Sugi Predict

Sugi Predict / Compounds / SCHEMBL140574

SCHEMBL140574

SCHEMBL140574

Clc1ncnc2ccc(I)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 1/20 0.53
▸ PDE4B Q07343 1/20 0.53
▸ PDE4C Q08493 1/20 0.53
▸ PDE4D Q08499 1/20 0.53
▸ PARP1 P09874 1/20 0.44
▸ ENPP1 P22413 2/20 0.39
▸ EGFR P00533 3/20 0.38
▸ MAP4K4 O95819 4/20 0.38
▸ DYRK1A Q13627 1/20 0.37
▸ AXL P30530 1/20 0.37
▸ MKNK1 Q9BUB5 1/20 0.37
▸ MKNK2 Q9HBH9 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ GLA P06280 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29390639 1.00 PDE4A (0.53) PDE4APDE4BPDE4CPDE4DPARP1
Hydrochloric Acid SCHEMBL17075825 0.98 PDE4A (0.52) PDE4APDE4BPDE4CPDE4DPARP1
SCHEMBL14304406 0.85 MAP4K4 (0.47) PDE4APDE4BPDE4CPDE4DMAP4K4
SCHEMBL145141 0.84 PDE4A (0.53) PDE4APDE4BPDE4CPDE4DPARP1
SCHEMBL18630257 0.81 PARP1 (0.48) PDE4APDE4BPDE4CPDE4DPARP1
SCHEMBL856909 0.79 PDE4A (0.57) PDE4APDE4BPDE4CPDE4DPARP1
SCHEMBL29793572 0.79 PDE4A (0.57) PDE4APDE4BPDE4CPDE4DPARP1
SCHEMBL6978920 0.76 PARP1 (0.44) PARP1EGFRMAP4K4SMN1; SMN2CYP1A2
SCHEMBL217203 0.76 PARP1 (0.44) PARP1EGFRMAP4K4LMNACCNC
SCHEMBL28532923 0.76 PARP1 (0.44) PDE4APDE4BPDE4CPDE4DPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 632 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116239594-A 6- (imidazo [1,2-a ] pyridin-6-yl) quinazoline derivatives and uses thereof 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2023-06-09 — — CN claimed
WO-2022029795-A1 An environment friendly process for the preparation of Lapatinib Ditosylate of Formula 1(b) SUMAR BIOTECH LLP (IN) 2022-02-10 — — WO claimed
CN-111138420-A C13Isotope labeled lapatinib synthesis method 北京凯吉特医药科技发展有限公司 2020-05-12 — — CN claimed
CN-105237573-A Preparation method for di-p-toluenesulfonic acid derivative gefitinib JIANGSU KANION PHARMACEUTICAL 2016-01-13 — — CN claimed
CN-102924387-B 4-(3-chloro-4-methoxyanilino)-6-(3,4-substituted phenyl)quinazoline and salts thereof, preparation method and applications HUANG WEIYAN 2015-07-01 — — CN claimed
US-8927558-B2 Methods for detecting and reducing impurities of Lapatinib and salts thereof F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) 2015-01-06 — — US claimed
CN-102702116-B 4-(3-chloro-4-methoxylanilino)-6-(3-amidophenyl)quinazoline compound or pharmaceutically-acceptable salt thereof and preparation methods and applications thereof UNIV SOUTH CHINA TECH 2014-12-31 — — CN claimed
EP-2489661-B1 Impurity of lapatinib and salts thereof ITALIANA SINT SPA (IT) 2013-11-13 — — EP claimed
CN-102321076-B Preparation method of lapatinib intermediate and analogues thereof USTC UNIV SCIENCE TECH CN 2013-08-21 — — CN claimed
CN-102924387-A 4-(3-chloro-4-methoxyanilino)-6-(3,4-substituted phenyl)quinazoline and salts thereof, preparation method and applications HUANG WEIYAN 2013-02-13 — — CN claimed
US-20120295928-A1 METHODS FOR DETECTING AND REDUCING IMPURITIES OF LAPATINIB AND SALTS THEREOF F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2012-11-22 — — US claimed
CN-102702116-A 4-(3-chloro-4-methoxylanilino)-6-(3-amidophenyl)quinazoline compound or pharmaceutically-acceptable salt thereof and preparation methods and applications thereof UNIV SOUTH CHINA TECH 2012-10-03 — — CN claimed
CN-102702179-A 4-(3-chloro-4-methoxylanilino)-6-(furan-2-radical)quinazoline compound or pharmaceutically-acceptable salt thereof and preparation methods and applications thereof UNIV SOUTH CHINA TECH 2012-10-03 — — CN claimed
EP-2489661-A1 Impurity of lapatinib and salts thereof F.I.S. Fabbrica Italiana Sintetici S.p.A. (IT) 2012-08-22 — — EP claimed
CN-102321076-A The preparation method of lapatinibditosylate midbody and analogue thereof USTC UNIV SCIENCE TECH CN 2012-01-18 — — CN claimed
US-20100197915-A1 LAPATINIB INTERMEDIATES TEVA PHARMACEUTICALS USA, INC. 2010-08-05 — — US claimed
WO-2010017387-A2 LAPATINIB INTERMEDIATES TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2010-02-11 — — WO claimed
CN-122059948-A Fluorescent dye for targeting human EGFR 2 as well as preparation method and application thereof 宁波市医疗中心李惠利医院(宁波大学附属李惠利医院) 2026-05-19 — — CN disclosed
WO-1996028430-A1 TRISUBSTITUTED PHENYL DERIVATIVES NOVARTIS AG (CH) 1996-09-19 — — WO disclosed
WO-1996009294-A1 SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE THE WELLCOME FOUNDATION LIMITED (GB) 1996-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295928-A1 METHODS FOR DETECTING AND REDUCING IMPURITIES OF LAPATINIB AND SALTS THEREOF SRMS, ABL1, ERBB2 PDE4A 2927/4885PDE4B 2622/4885PDE4C 2730/4885
US-20100197915-A1 LAPATINIB INTERMEDIATES ERBB2, ABL1, EGFR PDE4A 4249/4885PDE4B 4116/4885PDE4C 3934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.